Investors' pessimism about the company's revenue prospects may be causing the low P/S ratio. The company's forecast growth is lower than the wider industry, which could be contributing to the depressed P/S. It's hard to see the share price rising strongly in the near future given these circumstances.
$Regenxbio(RGNX.US)$pivotal topline result from CAMPSIIT trial are coming. RGX-121 for the treatment a rare genetic disease showing meaningful results. Prior FDA granted Renerative medicine advanced therapy decignition for RGX-121. Let’s see…
Despite REGENXBIO's revenue growth, its significant share price drop over the past five years suggests possible over-hype. The company's poor performance over the past year, even as the market gained, could be a warning for long-term investors.
Regenxbio股票讨论区
$EyePoint Pharmaceuticals(EYPT.US)$
$Adverum Biotechnologies(ADVM.US)$
$Regenxbio(RGNX.US)$
$4D Molecular Therapeutics(FDMT.US)$
$Kodiak Sciences(KOD.US)$
$Regenxbio(RGNX.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood医药(IRWD.US)$ Phase 3
$阿里拉姆制药(ALNY.US)$ Phase 3
$福泰制药(VRTX.US)$ Phase 3
$KalVista Pharmaceuticals(KALV.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$罗氏(ADR)(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$Applied Therapeutics(APLT.US)$ Phase 3
$阿卡迪亚(ACAD.US)$ Phase 3...
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制药(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...
暂无评论